BRPI0515012A - substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso - Google Patents
substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e usoInfo
- Publication number
- BRPI0515012A BRPI0515012A BRPI0515012-4A BRPI0515012A BRPI0515012A BR PI0515012 A BRPI0515012 A BR PI0515012A BR PI0515012 A BRPI0515012 A BR PI0515012A BR PI0515012 A BRPI0515012 A BR PI0515012A
- Authority
- BR
- Brazil
- Prior art keywords
- atp
- enzyme
- chemical substance
- formulation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SUBSTáNCIA QUìMICA, COMPOSIçãO E FORMULAçãO FARMACêUTICA, MéTODO DE TRATAMENTO, MéTODO DE INIBIçãO DE PELO MENOS UMA ENZIMA QUE UTILIZA ATP E USO São descritos compostos com base em aril-tiazol 2-amido-4-substituído que exibem atividade inibidora de enzimas que utilizam ATP métodos de uso de compostos que exibem atividade inibidora de enzimas que utilizam ATP e composições que compreendem compostos que exibem atividade inibidora de enzimas que utilizam ATP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60126604P | 2004-08-13 | 2004-08-13 | |
US60883404P | 2004-09-10 | 2004-09-10 | |
PCT/US2005/028549 WO2006020767A2 (en) | 2004-08-13 | 2005-08-11 | Thiazole based inhibitors of atp-utilizing enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515012A true BRPI0515012A (pt) | 2008-07-01 |
Family
ID=35908138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515012-4A BRPI0515012A (pt) | 2004-08-13 | 2005-08-11 | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso |
Country Status (16)
Country | Link |
---|---|
US (2) | US7410988B2 (pt) |
EP (3) | EP2620150A3 (pt) |
JP (1) | JP2008509923A (pt) |
KR (1) | KR20070049655A (pt) |
AR (1) | AR050917A1 (pt) |
AU (1) | AU2005272815A1 (pt) |
BR (1) | BRPI0515012A (pt) |
CA (1) | CA2575466A1 (pt) |
ES (1) | ES2401138T3 (pt) |
IL (1) | IL180946A0 (pt) |
MX (1) | MX2007001727A (pt) |
RU (1) | RU2007109073A (pt) |
SG (1) | SG155222A1 (pt) |
TW (1) | TW200621253A (pt) |
WO (1) | WO2006020767A2 (pt) |
ZA (1) | ZA200701189B (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090118139A1 (en) * | 2000-11-07 | 2009-05-07 | Caliper Life Sciences, Inc. | Microfluidic method and system for enzyme inhibition activity screening |
AU2004296764B2 (en) * | 2003-12-02 | 2011-04-28 | The Ohio State University Research Foundation | Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
ES2401138T3 (es) * | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
CA2585983C (en) * | 2004-11-10 | 2014-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
AU2006272609A1 (en) * | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Abl kinase inhibition |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
EP1909910A1 (en) * | 2005-08-04 | 2008-04-16 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
EP1937270A1 (en) * | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP5199885B2 (ja) | 2006-01-18 | 2013-05-15 | アムジエン・インコーポレーテツド | プロテインキナーゼb(pkb)阻害剤としてのチアゾール化合物 |
WO2007116901A1 (ja) * | 2006-04-05 | 2007-10-18 | Banyu Pharmaceutical Co., Ltd. | 新規アリールアミド誘導体 |
MX2008013400A (es) | 2006-04-19 | 2008-11-10 | Astellas Pharma Inc | Derivado de azolcarboxamida. |
US8198252B2 (en) * | 2006-05-19 | 2012-06-12 | Board Of Regents, The University Of Texas System | SIRNA inhibition of PI3K P85, P110, and AKT2 and methods of use |
AU2007286111A1 (en) * | 2006-08-16 | 2008-02-21 | Genentech, Inc. | 2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
RU2009110254A (ru) | 2006-08-24 | 2010-09-27 | Новартис АГ (CH) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений |
US7985767B2 (en) * | 2006-09-06 | 2011-07-26 | Allergan, Inc. | Therapeutic amides |
AU2007299870A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
JP2010513403A (ja) | 2006-12-20 | 2010-04-30 | ノバルティス アーゲー | Scd阻害剤としての2−置換5員ヘテロ環 |
US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
PT2078010E (pt) | 2006-12-29 | 2014-05-07 | Rigel Pharmaceuticals Inc | Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl |
CA2691251A1 (en) * | 2007-06-19 | 2008-12-24 | Yoshikazu Ohta | Preventive/remedy for cancer |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
CA2693473A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
MX2010004499A (es) | 2007-10-24 | 2010-05-20 | Astellas Pharma Inc | Compuesto de azolcarboxamida o sal de el. |
SI2205592T1 (sl) * | 2007-10-26 | 2013-09-30 | Rigel Pharmaceuticals, Inc. | Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji |
US7998688B2 (en) * | 2008-03-07 | 2011-08-16 | OSI Pharmaceuticals, LLC | Inhibition of EMT induction in tumor cells by anti-cancer agents |
US8232402B2 (en) | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
CA2743717A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
PE20120057A1 (es) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina |
JP5683489B2 (ja) * | 2009-01-12 | 2015-03-11 | アレイ バイオファーマ、インコーポレイテッド | ピペリジン含有化合物およびその用途 |
US8546433B2 (en) | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
PE20130405A1 (es) * | 2010-04-07 | 2013-04-10 | Hoffmann La Roche | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso |
WO2011149874A2 (en) * | 2010-05-26 | 2011-12-01 | Schering Corporation | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
CN103003270B (zh) | 2010-07-22 | 2014-11-12 | 扶桑药品工业株式会社 | 苯并呋喃酮化合物以及含有该化合物的药物组合物 |
US9790218B2 (en) | 2011-08-05 | 2017-10-17 | The Regents Of The University Of California | Small molecule activators of calcium-activated chloride channels and methods of use |
US10172984B2 (en) * | 2011-08-31 | 2019-01-08 | Kci Licensing, Inc. | Reduced-pressure treatment and debridement systems and methods |
KR101472175B1 (ko) | 2012-02-17 | 2014-12-15 | 중앙대학교 산학협력단 | 신규한 2-아미노티아졸 유도체 및 이를 유효성분으로 포함하는 항암용 조성물 |
US20150293120A1 (en) * | 2012-03-27 | 2015-10-15 | Protagen Ag | Marker sequences for rheumatoid arthritis |
JPWO2013146754A1 (ja) * | 2012-03-27 | 2015-12-14 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
WO2014069434A1 (ja) * | 2012-10-30 | 2014-05-08 | カルナバイオサイエンス株式会社 | 新規チアゾリジノン誘導体 |
ES2716762T3 (es) | 2013-02-04 | 2019-06-14 | Janssen Pharmaceutica Nv | Moduladores de FLAP |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
WO2017147526A1 (en) * | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
IT201700039329A1 (it) * | 2017-04-10 | 2018-10-10 | Univ Pisa | Derivati benzofuranici quali attivatori di ampk |
WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
WO2019169135A1 (en) * | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
CN109394764B (zh) * | 2018-09-03 | 2021-01-15 | 温州医科大学 | 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类化合物在药物制备中的应用 |
IL310370A (en) * | 2021-07-27 | 2024-03-01 | Gate Bioscience Inc | Inhibitors of protein expression |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2073284B1 (pt) * | 1969-12-23 | 1973-07-13 | Ferlux | |
US4243406A (en) * | 1978-12-26 | 1981-01-06 | Monsanto Company | 5-Aryl-4-isoxazolecarboxylate-safening agents |
DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
US4914112A (en) | 1986-06-03 | 1990-04-03 | Sumitomo Pharmaceuticals Company, Limited | Aminoazole derivatives and their production and use |
EP0352581A3 (de) * | 1988-07-28 | 1990-07-04 | F. Hoffmann-La Roche Ag | Aethylendiaminmonoamid-Derivate |
IL94051A0 (en) | 1989-04-12 | 1991-01-31 | Beecham Group Plc | 1-normon-2-yl-heterocycles,process for their preparation and pharmaceutical compositions containing them |
US5338857A (en) * | 1989-08-04 | 1994-08-16 | Mitsui Toatsu Chemicals Incorporated | Aminoketone derivatives of 1,2-oxazole and use thereof |
IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
IT1263089B (it) | 1993-04-26 | 1996-07-24 | Menarini Farma Ind | Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono. |
JPH07149745A (ja) | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−アミノチアゾール誘導体 |
ES2186720T3 (es) | 1994-05-27 | 2003-05-16 | Merck & Co Inc | Composiciones para inhibir la reabsorcion osea mediada por osteoclastos. |
WO1996016650A1 (fr) | 1994-11-29 | 1996-06-06 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive |
JPH0987282A (ja) * | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
JP4136024B2 (ja) | 1995-12-29 | 2008-08-20 | 富山化学工業株式会社 | 2−アミノチアゾ−ル誘導体またはその塩 |
CN1209744A (zh) | 1995-12-29 | 1999-03-03 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
AU2116497A (en) | 1996-01-31 | 1997-08-22 | Population Council, The | Multivalent chimeric peptides as microbicides |
JPH10287634A (ja) | 1997-04-11 | 1998-10-27 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体 |
US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
WO2001010865A1 (fr) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
EP1088822A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl hydrazide derivatives |
TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
US6365591B1 (en) * | 1999-10-18 | 2002-04-02 | Recordati, S.A., Chemical And Pharmacueticals Company | Isoxazolecarboxamide derivatives |
WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
DE10019755A1 (de) | 2000-04-20 | 2001-11-08 | Bayer Ag | Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten |
ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
JP2002053566A (ja) * | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
JP2002302445A (ja) * | 2001-02-02 | 2002-10-18 | Takeda Chem Ind Ltd | Jnk阻害剤 |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
US20050080113A1 (en) * | 2001-06-11 | 2005-04-14 | Shigenori Ohkawa | Medicinal compositions |
JP2003063993A (ja) * | 2001-06-11 | 2003-03-05 | Takeda Chem Ind Ltd | 医薬組成物 |
WO2002101007A2 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc | Antipathogenic benzamide compounds |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
JP3901964B2 (ja) | 2001-08-15 | 2007-04-04 | 日鐵溶接工業株式会社 | 亜鉛メッキ層がある当接部のレーザ溶接方法 |
CN1659145A (zh) | 2001-11-27 | 2005-08-24 | 惠氏控股公司 | 作为egf-r和her2激酶抑制剂的3-氰基喹啉 |
EP1452530A4 (en) | 2001-12-03 | 2005-11-30 | Japan Tobacco Inc | AZOL CONNECTION AND THEIR MEDICAL USE |
CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
US6995181B2 (en) * | 2002-07-18 | 2006-02-07 | Bristol-Myers Squibb Co. | Modulators of the glucocorticoid receptor and method |
WO2004013141A1 (en) | 2002-08-06 | 2004-02-12 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
DE60327443D1 (de) | 2002-09-18 | 2009-06-10 | Pfizer Prod Inc | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) |
OA12937A (en) | 2002-10-09 | 2006-10-13 | Pfizer Prod Inc | Thiazole compounds for the treatment of neurodegenerative disorders. |
WO2004037250A1 (en) | 2002-10-23 | 2004-05-06 | Beyond Genomics, Inc. | 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof |
AR043057A1 (es) * | 2002-10-30 | 2005-07-13 | Vertex Pharma | Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
CA2514363A1 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
MXPA05013645A (es) * | 2003-06-20 | 2006-02-24 | Galderma Res & Dev | Nuevos compuestos moduladores de los receptores de tipo ppar gama y su utilizacion en composiciones cosmeticas o farmaceuticas. |
AU2004267094A1 (en) * | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
US7351727B2 (en) | 2003-09-02 | 2008-04-01 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
AU2004276337B2 (en) * | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2005040161A1 (en) * | 2003-10-27 | 2005-05-06 | S*Bio Pte Ltd | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
AU2005236002A1 (en) * | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
MX2007000092A (es) * | 2004-06-30 | 2007-03-07 | Vertex Pharma | Azaindoles utiles como inhibidores de proteinas cinasas. |
ES2401138T3 (es) * | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
AU2007286111A1 (en) * | 2006-08-16 | 2008-02-21 | Genentech, Inc. | 2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
-
2005
- 2005-08-11 ES ES09178829T patent/ES2401138T3/es active Active
- 2005-08-11 BR BRPI0515012-4A patent/BRPI0515012A/pt not_active IP Right Cessation
- 2005-08-11 EP EP12197588.2A patent/EP2620150A3/en not_active Withdrawn
- 2005-08-11 CA CA002575466A patent/CA2575466A1/en not_active Abandoned
- 2005-08-11 EP EP05803385A patent/EP1781287A4/en not_active Ceased
- 2005-08-11 SG SG200905453-7A patent/SG155222A1/en unknown
- 2005-08-11 US US11/202,927 patent/US7410988B2/en not_active Expired - Fee Related
- 2005-08-11 EP EP09178829A patent/EP2168578B1/en active Active
- 2005-08-11 KR KR1020077005466A patent/KR20070049655A/ko not_active Application Discontinuation
- 2005-08-11 RU RU2007109073/04A patent/RU2007109073A/ru not_active Application Discontinuation
- 2005-08-11 AR ARP050103368A patent/AR050917A1/es unknown
- 2005-08-11 WO PCT/US2005/028549 patent/WO2006020767A2/en active Application Filing
- 2005-08-11 JP JP2007525789A patent/JP2008509923A/ja active Pending
- 2005-08-11 AU AU2005272815A patent/AU2005272815A1/en not_active Abandoned
- 2005-08-11 MX MX2007001727A patent/MX2007001727A/es active IP Right Grant
- 2005-08-12 TW TW094127402A patent/TW200621253A/zh unknown
-
2007
- 2007-01-25 IL IL180946A patent/IL180946A0/en unknown
- 2007-02-09 ZA ZA2007/01189A patent/ZA200701189B/en unknown
-
2008
- 2008-07-03 US US12/167,908 patent/US7795290B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ZA200701189B (en) | 2008-09-25 |
EP1781287A4 (en) | 2008-02-27 |
US20090048313A1 (en) | 2009-02-19 |
WO2006020767A2 (en) | 2006-02-23 |
SG155222A1 (en) | 2009-09-30 |
TW200621253A (en) | 2006-07-01 |
EP2168578B1 (en) | 2012-12-19 |
IL180946A0 (en) | 2007-07-04 |
KR20070049655A (ko) | 2007-05-11 |
EP2168578A2 (en) | 2010-03-31 |
US7410988B2 (en) | 2008-08-12 |
EP1781287A2 (en) | 2007-05-09 |
US20060052416A1 (en) | 2006-03-09 |
US7795290B2 (en) | 2010-09-14 |
EP2168578A3 (en) | 2010-10-27 |
JP2008509923A (ja) | 2008-04-03 |
CA2575466A1 (en) | 2006-02-23 |
RU2007109073A (ru) | 2008-09-20 |
AU2005272815A1 (en) | 2006-02-23 |
EP2620150A3 (en) | 2014-01-08 |
AR050917A1 (es) | 2006-12-06 |
WO2006020767A3 (en) | 2006-11-09 |
EP2620150A2 (en) | 2013-07-31 |
MX2007001727A (es) | 2007-04-20 |
ES2401138T3 (es) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515012A (pt) | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
ECSP20027480A (es) | Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa | |
ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
ATE478664T1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
MY154869A (en) | Composition for treating metabolic syndrome | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
DE602005014382D1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren | |
NO20050290L (no) | Nye tetrahydropyridin-derivater som renin-inhibitorer | |
YU49101A (sh) | Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze | |
CL2007002062A1 (es) | Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
BRPI0410078A (pt) | uso de efetuadores de ciclases de glutaminila e glutamato | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
DE60314623D1 (de) | Substituierte pyrazolopyrimidine | |
BR0306785A (pt) | Deazapurinas e seus usos | |
DE60007095D1 (de) | Calanolide zur hemmung von btk | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
ATE548034T1 (de) | Pharmazeutische zusammensetzungen mit droxidopa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014. |